Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

BACKGROUND: The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initial estimate of the dose-toxicity relationship (prior skeleton) is required, and...

Descripción completa

Detalles Bibliográficos
Autores principales: James, G. D., Symeonides, S., Marshall, J., Young, J., Clack, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786936/
https://www.ncbi.nlm.nih.gov/pubmed/33402104
http://dx.doi.org/10.1186/s12885-020-07703-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786936/
https://www.ncbi.nlm.nih.gov/pubmed/33402104
http://dx.doi.org/10.1186/s12885-020-07703-6

Ejemplares similares